SOTIO Biotech has just announced that the first patient has received the first dose of treatment in their Phase 1/2 trial for SOT102. SOT102 is an investigative treatment for pancreatic and gastric cancer. The trial is called CLAUDIO-01.

SOT102

SOT102 is a drug that targets CLDN18.2. It is an antibody-drug conjugate which has demonstrated positive preclinical results of anti-tumor efficacy both in vivo and in vitro. CLDN18.2 is such a promising target in these cancers because it is expressed so prevalently within the gastrointestinal tract.

Preclinical data has shown that SOT102 is safer than the standard of care for these cancers. It has also shown to be more effective in preclinical data. This new clinical trial is a huge next step in the development of this therapy as a potential treatment option.

CLAUDIO-01

This trial is the very first human trial investigating the efficacy of this new treatment. It will be conducted at multiple trial sites in France, the Czech Republic, Belgium, the United States, and Spain. It will evaluate this therapy both on its own and when it is used with the standard of care treatments for these cancers.

The investigation will include 109 patients who are diagnosed with pancreatic adenocarcinoma, gastric adenocarcinoma, or adenocarcinoma of gastroesophageal junction (GEJ).

The first patient was dosed with the treatment in the Czech Republic at Masaryk Memorial Cancer Institute. They were dosed under supervision from the principal investigator, Dr. Radka OBermannova.

You can read more about this trial and this investigative therapy here.